OncoMatch/Clinical Trials/NCT06341894
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Is NCT06341894 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dalpiciclib and Endocrine therapy for early breast cancer.
Treatment: Dalpiciclib · Endocrine therapy — The investigator conduct a phase II multi-center, open-label trial to evaluate efficacy and safety of dalpiciclib with endocrine therapy as adjuvant treatment in patients with medium /high risk hormone receptor-positive, HER2-negative Early Breast Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER ≥10%)
immunohistochemical ER and/or PR≥10%
Required: PR (PGR) overexpression (PR ≥10%)
immunohistochemical ER and/or PR≥10%
Required: HER2 (ERBB2) wild-type
HER2-
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC
Excluded: Stage IV
anatomic stages of IIA-IIIC stage (T2-4N0-3M0), of which stage IIA only included T1N1M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify